The significance of SIRI and SII scores in predicting the effect of omalizumab treatment in patients with severe allergic asthma
Allergologia et Immunopathologia, cilt.52, sa.4, 2025 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 52 Sayı: 4
- Basım Tarihi: 2025
- Doi Numarası: 10.15586/aei.v53i4.1325
- Dergi Adı: Allergologia et Immunopathologia
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, DIALNET
- Anahtar Kelimeler: asthma control test, severe asthma, Omalizumab, SIRI, SII
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Objective: To evaluate the role of systemic inflammation response index (SIRI) and systemic immune-inflammation index (SII) biomarkers in predicting the response to omalizumab (OMA) treatment in patients with severe allergic asthma. Methods: A retrospective analysis was conducted to examine the correlation between the fourth-month treatment responses of patients undergoing OMA therapy for severe allergic asthma and their baseline neutrophil, lymphocyte, monocyte, and platelet values, as well as SIRI and SII scores. Results: Posttreatment asthma control scores had a positive correlation with baseline SIRI (p = 0.03, r = 0.358), SII (p = 0.04, r = 0.345), and serum neutrophil values (p = 0.01, r = 0.308), and a negative correlation with lymphocyte values (p = 0.00, r = −0.398). Baseline SII showed a negative correlation with posttreatment systemic steroid usage (mg) (p = 0.04, r = −0.247) and the number of exacerbations (p = 0.02, r = −0.269). Conclusion: SIRI and SII scores hold promise for predicting the success of OMA therapy; however, their utility needs to be validated in larger patient cohorts and further studies.